Washington University School of Medicine: Lymphoma, Non-Hodgkin trials

The registry lists 15 Lymphoma, Non-Hodgkin studies with Washington University School of Medicine as lead sponsor. 2 are open to participants now and 7 have results posted.

Early Phase 1 1Phase 1 8Phase 2 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced CardiotoxicityNot yet recruitingNCT07838649Phase 1
• NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell LymphomaRecruitingNCT07052305Phase 1
• BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic LymphomaTerminatedNCT02763384Phase 2Results posted
• Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological MalignanciesCompletedNCT02639559Phase 2Results posted
• Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin LymphomaCompletedNCT02098109Phase 2Results posted
• Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for LymphomaCompletedNCT01969435Phase 2Results posted
• Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling DonorsCompletedNCT01158118Phase 2Results posted
• Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With LymphomaCompletedNCT00733824Phase 1/2Results posted
• Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological MalignanciesCompletedNCT00241358Phase 1/2Results posted
• 64Cu-LLP2A for Imaging Hematologic MalignanciesTerminatedNCT06636175Early Phase 1
• Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)Active, not recruitingNCT06040320Phase 1/2
• Duvelisib Following Chimeric Antigen Receptor T-Cell TherapyActive, not recruitingNCT05044039Phase 1
• Phase I/II Study of Abraxane in Recurrent and Refractory LymphomaTerminatedNCT01555853Phase 1
• Tandem Stem Cell Transplantation for Non-Hodgkin's LymphomaActive, not recruitingNCT00882895Phase 2
• Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed DiseaseCompletedNCT00871702Phase 1